Last updated on April 2020

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Brief description of study

This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy

Clinical Study Identifier: NCT03759288

Find a site near you

Start Over

Clinical Trials Specialist

Los Angeles, CA United States
  Connect »

Gastrointestinal Biosciences

Los Angeles, CA United States
  Connect »